Novacyt, Co-Diagnostics, Other Test Firms Seek Fast-Track EUA Approval From FDA For Coronavirus Dx's
Executive Summary
Diagnostics companies around the world – including Novacyt, Roche, Co-Diagnostics and Mammoth Biosciences – are developing and launching tests to fight the coronavirus in China and other countries as quickly as possible, and some are seeking Emergency Use Authorization (EUA) approval from the FDA so their assays can be used on US patients.
You may also be interested in...
The Cost Of Coronavirus: Medtech Market Wins And Losses
With the rapid global spread of the coronavirus, Medtech Insight looks at the predicted economic impact of the outbreak on the industry’s biggest businesses.
CDC Urges Diagnostics Makers To Scale Up Coronavirus Test
The second in command at the US Centers for Disease Control and Prevention said with the help of the Chinese government, the agency was quickly able to develop a diagnostic test for the new coronavirus – but now the private sector should use its resources to scale up production of the tests.
FDA Responds To Coronavirus By Getting Out First Emergency-Use Novel Coronavirus Diagnostic
The US agency on 4 February issued its first Emergency Use Authorization of a 2019-novel coronavirus test by enabling emergency use of the Centers for Disease Control and Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel. The move will allow use of the test at any CDC-qualified lab across the US.